Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 144-151

  Zheng, Jia Hua ^a   Guida, Louis A ^a   Rower, Caitlin ^a   Castillo Mancilla, Jose ^b   Meditz, Amie ^b   Klein, Brandon ^a   Kerr, Becky Jo ^a   Langness, Jacob ^c   Bushman, Lane ^a   Kiser, Jennifer ^a   Anderson, Peter L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Analytical method; Antiretroviral therapy; Dried blood spot; LC MS MS; Nucleoside analog

Indexed keywords

EMTRICITABINE; TENOFOVIR;

ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; HEMATOCRIT; HUMAN; LIMIT OF QUANTITATION; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANALYTICAL METHOD; ANTIRETROVIRAL THERAPY; DRIED BLOOD SPOT; LC-MS/MS; NUCLEOSIDE ANALOG;

ADENINE; CALIBRATION; CHROMATOGRAPHY, LIQUID; DEOXYCYTIDINE; DRIED BLOOD SPOT TESTING; DRUG STABILITY; HEMATOCRIT; HUMANS; ORGANOPHOSPHONATES; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TEMPERATURE;

EID: 84884341966     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.08.033     Document Type: Article

References (19)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2013, Department of Health and Human Services, (updated 12.02.13. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf accessed 22.05.13).
2. ® (tenofovir disoproxil fumarate) product information 2012, Gilead Sciences, Foster City, CA, (November).
3. ® (tenofovir disoproxil fumarate and emtricitabine) product information 2012, Gilead Sciences, Foster City, CA, (July).
4. Flynn P.M., Mirochnick M., Shapiro D.E., Bardeguez A., Rodman J., Robbins B., et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob. Agents Chemother. 2011, 55:5914-5922.
5. Hirt D., Ekouévi D.K., Pruvost A., Urien S., Arrivé E., Blanche S., et al. Plasma and Intracellular Tenofovir Pharmacokinetics in the Neonate (ANRS 12109 Trial, Step 2). Antimicrob. Agents Chemother. 2011, 55:2961-2967.
6. King J.R., Yogev R., Jean-Philippe P., Graham B., Wiznia A., Britto P., et al. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrob. Agents Chemother. 2011, 55:4290-4294.
7. Li W., Tse F.L. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 2010, 24:49-65.
8. Castillo-Mancilla J.R., Zheng J.H., Rower J.E., Meditz A., Gardner E.M., Predhomme J., et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res. Hum. Retroviruses 2013, 29:384-390.
9. Bushman L.R., Kiser J.J., Rower J.E., Klein B., Zheng J.H., Ray M.L., et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J. Pharm. Biomed. Anal. 2011, 56:390-401.
10. Delahunty T., Bushman L.R., Robbins B., Fletcher C.V. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J. Chromatogr. B 2009, 877:1907-1914.
11. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 2007, 24:1962-1973.
12. Holub M., Tuschl K., Ratschmann R., Strnadova K.A., Muhl A., Heinze G., et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin. Chim. Acta 2006, 373:27-31.
13. Liu G., Snapp H.M., Ji Q.C. Internal standard tracked dilution to overcome challenges in dried blood spots and robotic sample preparation for liquid chromatography/tandem mass spectrometry assays. Rapid Commun. Mass Spectrom. 2011, 25:1250-1256.
14. ter Heine R., Rosing H., van Gorp E.C., Mulder J.W., van der Steeg W.A., Beijnen J.H., et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 867:205-212.
15. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
16. Bennetto-Hood C., Long M.C., Acosta E.P. Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma. Rapid Commun. Mass Spectrom. 2007, 21:2087-2094.
17. Gomes N.A., Vaidya V.V., Pudage A., Joshi S.S., Parekh S.A. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study. J. Pharm. Biomed. Anal. 2008, 48:918-926.
18. Durand-Gasselin L., Da Silva D., Benech H., Pruvost A., Grassi J. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob. Agents Chemother. 2007, 51:2105-2111.
19. Anderson P.L., Meditz A., Kiser J.J., Zheng J.H., Predhomme J., Gardner E.M., et al. The single dose pharmacokinetic profile of intracellular tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in HIV-negative volunteers. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections 2011.